Post hoc analysis of 12 990 patients with type 2 diabetes and CKD in FIDELITY: finerenone vs placebo reduced cardiovascular and kidney composite events consistently across CKM stages 2–4 (P interaction .86 and .65), with greater CKM regression at 3 years (11.4% vs 7.4%).
Secondary analysisn = 12,990
Lo et al. Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical Trials